Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01551745
Other study ID # CL-PTL 112
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date March 2012
Est. completion date April 2016

Study information

Verified date October 2021
Source Gradalis, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a Phase II study of Vigil™ autologous tumor cell vaccine integrated with bevacizumab. All patients will have had Vigil™ prepared and stored from initial primary surgical debulking. Patients meeting eligibility criteria will receive Vigil™ 1.0 x 10e7 cells/intradermal injection once every 4 weeks and bevacizumab 10 mg/kg intravenously every 2 weeks.


Recruitment information / eligibility

Status Completed
Enrollment 5
Est. completion date April 2016
Est. primary completion date April 2016
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Histologically confirmed papillary serous or endometrioid ovarian cancer. 2. Previous randomization to Gradalis, Inc. protocol CL-PTL 105; observation arm (Group B) or patients with vaccine prepared for CLPTL 105 but not otherwise qualifying. 3. Recurrent cisplatinum resistant/refractory disease (defined as the appearance of any measurable or evaluable lesion or as asymptomatic CA-125 levels greater than 100 u/mL at two consecutive measurements with no intervening therapy. 4. Successful manufacturing of 4 vials of Vigil™ vaccine. 5. Recovered from all clinically relevant toxicities related to prior therapies. 6. ECOG PS 0-2 prior to Vigil™ vaccine administration. 7. Normal organ and marrow function as defined below: 1. Absolute granulocyte count =1,500/mm3 2. Absolute lymphocyte count = 200/mm3 3. Platelets =100,000/mm3 4. Total bilirubin =1.5 x ULN 5. AST(SGOT)/ALT(SGPT)/alkaline phosphatase =2.5 x ULN 6. Creatinine <1.5 mg/dL 7. INR < 1.5 8. Baseline blood pressure must be under 140/90 9. Urine protein-to-creatinine ratio < 1.0 mg/dL. 10. Patients must be off all "statin" drugs for = 2 weeks prior to initiation of therapy. 11. Ability to understand and the willingness to sign a written informed protocol specific consent. Exclusion Criteria: 1. Surgery involving general anesthesia, chemotherapy, radiotherapy, steroid therapy, or immunotherapy within 4 weeks prior to vaccination. Chemotherapy within 3 weeks prior to vaccination. Steroid therapy within 1 week prior to vaccination. 2. Major surgery within 6 weeks or minor surgery within 2 weeks of receiving bevacizumab. 3. Patient must not have received any other investigational agents within 4 weeks prior to study entry. 4. Patients who require parenteral hydration of nutrition and have evidence of partial bowel obstruction or perforation. 5. Patients with history of brain metastases. 6. Patients with compromised pulmonary disease. 7. Short term (<30 days) concurrent systemic steroids = 0.25 mg/kg prednisone per day (maximum 7.5 mg/day) and bronchodilators (inhaled steroids) are permitted; other steroid regimens and/or immunosuppressives are excluded. 8. Prior splenectomy. 9. Prior malignancy (excluding nonmelanoma carcinomas of the skin and carcinoma in situ cervix) unless in remission for = 2 years. 10. Kaposi's Sarcoma. 11. Patients with active bleeding or pathologic conditions that carry high risk of bleeding such as a known bleeding disorder, coagulopathy, or tumor involving major blood vessels. 12. History of Stroke/Transient Ischemic Attack 13. Use of bleeding diathesis 14. Use of anti-coagulants 15. Patients with clinically significant cardiovascular disease including any of the following: 1. Significant cardiac conduction abnormalities (e.g., PR interval > 0.24 sec or second or third degree AV block. 2. Uncontrolled hypertension, defined as systolic blood pressure (BP) > 150 mm Hg or diastolic BP > 90 mm Hg. 3. Myocardial infarction, cardiac arrhythmia, or unstable angina within the past 6 months. 4. New York Heart Association grade II or greater congestive heart failure. 5. Serious cardiac arrhythmia requiring medication. 6. Grade II or greater peripheral vascular disease except episodes of ischemia < 24 hours induration that are managed non-surgically and without permanent deficit 7. History of cerebrovascular accident within the past 6 months. 8. No significant traumatic injury within the past 28 days. 16. Uncontrolled infection or psychiatric illness/social situations that would limit compliance with study requirements. 17. Patients with known HIV. 18. Patients with chronic Hepatitis B and C infection. 19. Patients with uncontrolled autoimmune diseases.

Study Design


Intervention

Biological:
Vigil™ Vaccine
Patients meeting eligibility criteria will receive Autologous Vigil™ vaccine will be supplied by Gradalis,Inc. Patients will receive 1.0 x 10e7 cells via intradermal injection one day each cycle for a maximum of 12 doses as long as sufficient material is available and subject is clinically stable. Additionally, patients will receive bevacizumab 10 mg/kg intravenously (prior to Vigil™ administration) every 2 weeks (4 weeks=1 cycle).
Drug:
Bevacizumab
Patients meeting eligibility criteria will receive bevacizumab 10 mg/kg intravenously every 2 weeks.

Locations

Country Name City State
United States Mary Crowley Cancer Research Centers Dallas Texas

Sponsors (1)

Lead Sponsor Collaborator
Gradalis, Inc.

Country where clinical trial is conducted

United States, 

References & Publications (1)

Senzer N, Barve M, Kuhn J, Melnyk A, Beitsch P, Lazar M, Lifshitz S, Magee M, Oh J, Mill SW, Bedell C, Higgs C, Kumar P, Yu Y, Norvell F, Phalon C, Taquet N, Rao DD, Wang Z, Jay CM, Pappen BO, Wallraven G, Brunicardi FC, Shanahan DM, Maples PB, Nemunaitis J. Phase I trial of "bi-shRNAi(furin)/GMCSF DNA/autologous tumor cell" vaccine (FANG) in advanced cancer. Mol Ther. 2012 Mar;20(3):679-86. doi: 10.1038/mt.2011.269. Epub 2011 Dec 20. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Time to Progression Time to progression (TTP) following bevacizumab integrated with Vigil vaccine in patients failing standard of care in study CL-PTL 105 or in those not otherwise qualifying after vaccine production. This will be measured from the treatment start date (date of first dose) to either the date the patient is first recorded as having disease recurrence (even if the patient went off treatment because of toxicity), or the date of death if the patient dies due to any causes before progression. 24 months
Primary Response Rate Response will be evaluated using the revised Response Evaluation Criteria in Solid Tumors (RECIST) guideline. Up to 12 months
Secondary Number of Alive Subjects Survival status of patients after treatment was determined by following these patients up to 24 months. 24 months
Secondary Enzyme-Linked ImmunoSorbent Spot (ELISPOT) To determine if subjects will have a positive (defined as >10 ELISPOTS from baseline) immune response to Vigil. Blood was collected to compare ELISPOT results from baseline until 30 days after last dose. Baseline, End of Treatment (30 days after last dose) up to 12 months
See also
  Status Clinical Trial Phase
Completed NCT01010126 - Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer Phase 2
Terminated NCT00899093 - YKL-40 in Serum Samples From Patients With Newly Diagnosed Stage III-IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Receiving Chemotherapy
Completed NCT00301756 - Belinostat in Treating Patients With Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer or Ovarian Low Malignant Potential Tumors Phase 2
Completed NCT00262847 - Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Phase 3
Recruiting NCT01000259 - Study of Tumor Tissue Samples From Patients Who Have Undergone Surgery for Advanced Stage III or Stage IV Ovarian Epithelial Cancer N/A
Completed NCT00066456 - Radiation Therapy to the Abdomen Plus Docetaxel in Treating Patients With Recurrent or Persistent Advanced Ovarian, Peritoneal, or Fallopian Tube Cancer Phase 1
Withdrawn NCT00551265 - Oregovomab With or Without Cyclophosphamide in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Responded to Second-Line Chemotherapy N/A
Completed NCT03188432 - Hyperthermic Intraperitoneal Chemotherapy Trial Comparing Quality of Life in Patients With Stage IIIC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Phase 2
Completed NCT03297489 - Intravital Microscopy in Evaluating Patients With Primary Peritoneal, Fallopian Tube, or Stage IA-IV Ovarian Cancer Early Phase 1
Withdrawn NCT00053235 - Research Study in Patients With Advanced Ovarian Epithelial Cancer N/A
Completed NCT00194714 - Vaccine Therapy in Treating Patients With Stage IV HLA-A2 and HER2 Positive Breast or Ovarian Cancer Receiving Trastuzumab Phase 1/Phase 2
Terminated NCT02441140 - Detection of Tumor Associated Cell-free DNA in Peritoneal Fluid Obtained by Culdocentesis N/A
Completed NCT01131234 - Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors Phase 1
Recruiting NCT05659381 - Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer Phase 3
Terminated NCT00003532 - Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Ovarian Cancer Phase 2
Completed NCT01522820 - Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors Phase 1
Not yet recruiting NCT06315270 - To Explore the Feasibility of Dynamic Changes of TCR Diversity in Peripheral Blood in Monitoring Recurrence and Evaluating Prognosis of Epithelial Ovarian Cancer
Withdrawn NCT02872519 - PET Imaging of Ovarian Carcinoma With 18F-FSPG Early Phase 1
Withdrawn NCT02567396 - Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction Phase 1
Withdrawn NCT02470559 - Activated T-cell Therapy, Low-Dose Aldesleukin, and Sargramostim in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That is Stage III-IV, Refractory, or Recurrent Phase 1